# The Medicines (Products for Human Use — Fees) Regulations 1995, Paragraph 3: Marketing authorizations


Subject to paragraph 4, where a marketing authorization is held in respect of a derivative of a new active substance, the fee payable under regulation 14(3) shall be—
(a) where it is of the same dosage form as, but of a different strength of active ingredient or different combination of active ingredients from, that relating to the new active substance, £3,575;
(b) where it is of a different dosage form from that relating to the new active substance, £5,950.

---
Source: https://www.legislation.gov.uk/uksi/1995/1116/schedule/3/part/III/paragraph/3 (the official version)
Page: https://openlegislation.uk/medicines-products-for-human-use-fees-regulations-1995/schedule-3/part-III/paragraph-3
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.